FDA Approves Updated Labeling for Antiepileptic Drugs, Warning of Increased Suicide Risk

摘要

The FDA has approved updated labeling for antiepileptic drugs (AEDs)-including Lyrica (pregabalin, Pfizer) and gabapentin-warning of an increased risk of suicidal thoughts and behaviors. For many of these drugs, the FDA is also requiring manufacturers to develop medication guides for patients, to be given out each time the drug is dispensed.Anti-epileptic drugs are increasingly prescribed to treat chronic neuropathic pain conditions, fibromyalgia, and migraine, in addition to epilepsy and psychiatric disorders.